# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0...
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2...
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...
scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...